TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9357378

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (2 sprays per nostril bid)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 233
Study: 8238830

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg.kg‐1 and Alfentanil 50 micrograms.kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiopentone 5 mg.kg‐1 and Suxamethonium 1 mg.kg‐1
Number of subjects: 0
Study: 6354230

Group type: EXPERIMENTAL
Intervention: i.v. infusion of insulin, 70 mu. kg‐1h‐1 for the first 60 min and 35 mu. kg‐1h‐1 subsequently
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of patients
Number of subjects: 0
Study: 31403570

Group type: EXPERIMENTAL
Intervention: Impact exercises from the OPTIMA-Ex trial
Number of subjects: 15
Study: 30488952

Group type: EXPERIMENTAL
Intervention: Bioactive Glass (BG) with autologous platelet-rich fibrin (PRF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bioactive Glass (BG) alone
Number of subjects: 20
Study: 26965908

Group type: EXPERIMENTAL
Intervention: University-wide bystander behavior intervention consisting of a 30-min presentation on dating violence and a week-long 'red flag' social marketing campaign
Number of subjects: 329

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 329
Study: 27239994

Group type: EXPERIMENTAL
Intervention: Acetylcysteine (A)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard oral management (S)
Number of subjects: 75
Study: 25104916

Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Ondansetron (4 mg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Ondansetron (8 mg)
Number of subjects: 160
Study: 22661278

Group type: EXPERIMENTAL
Intervention: Reduced-intensity modified constraint-induced movement therapy (mCIMT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 66
Study: 19358788

Group type: EXPERIMENTAL
Intervention: Atomoxetine (80 mg daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 32
Study: 17666600

Group type: EXPERIMENTAL
Intervention: IV ferric carboxymaltose (less than or equal to 1,000 mg over 15 minutes, repeated weekly)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: IV ferric carboxymaltose
Number of subjects: 352

Group type: COMPARATOR
Intervention: Oral ferrous sulfate (FeSO(4) 325 mg orally thrice daily for 6 weeks)
Number of subjects: 352
Study: 16508277

Group type: EXPERIMENTAL
Intervention: Chlorhexidine‐gluconate (2%)‐based cavity disinfectant
Number of subjects: 35

Group type: COMPARATOR
Intervention: No disinfectant treatment (Control)
Number of subjects: 35
Study: 15567628

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low physical functioning and low global health status and quality of life
Number of subjects: 0
Study: 10852195

Group type: EXPERIMENTAL
Intervention: Hewlett Packard (HP) monitoring system
Number of subjects: 16

Group type: COMPARATOR
Intervention: Kontron Instruments (KI) monitoring system
Number of subjects: 16

Group type: COMPARATOR
Intervention: Marquette‐Hellige (MH) monitoring system
Number of subjects: 16
Study: 8814685

Group type: EXPERIMENTAL
Intervention: Carboplatin 400 mg/m2 as a single agent (CB)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Combination of carboplatin 300 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (CB‐EC)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 130
Study: 1856402

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 174

Group type: COMPARATOR
Intervention: No ischemia (postoperative)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Silent ischemia (postoperative)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Symptomatic ischemia (postoperative)
Number of subjects: 174
Study: 6416576

Group type: EXPERIMENTAL
Intervention: 111In granulocyte scanning
Number of subjects: 22
Study: 30898134

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) supplementation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study: 28648477

Group type: EXPERIMENTAL
Intervention: Early antibiotic administration (mean TTA 4.35h, 58.5% received first dose within 4h)
Number of subjects: 371
Study: 25714493

Group type: EXPERIMENTAL
Intervention: Invasive urodynamic testing
Number of subjects: 222

Group type: COMPARATOR
Intervention: Clinical assessment with non‐invasive tests (control arm)
Number of subjects: 222
Study: 23331192

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol (plus cyclic medroxyprogesterone) for 12 months
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 69
Study: 21639818

Group type: EXPERIMENTAL
Intervention: 1-week HF diet intervention
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 4-week HF diet intervention
Number of subjects: 17
Study: 16850522

Group type: EXPERIMENTAL
Intervention: Olanzapine (50 mg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Clozapine (450 mg/day)
Number of subjects: 13
Study: 12897981

Group type: EXPERIMENTAL
Intervention: Brace set at -5 degrees
Number of subjects: 44

Group type: COMPARATOR
Intervention: Straight brace (0 degrees)
Number of subjects: 44
Study: 11099588

Group type: EXPERIMENTAL
Intervention: Whey hydrolysate formula (n = 23)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard formula (n = 20)
Number of subjects: 43
Study: 8871187

Group type: EXPERIMENTAL
Intervention: Growth hormone (hGH) treatment for 2 years
Number of subjects: 25

Group type: COMPARATOR
Intervention: Before treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: After 2 years of hGH treatment
Number of subjects: 25
Study: 1642487

Group type: EXPERIMENTAL
Intervention: Model A of discharge planning rounds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Model B of discharge planning rounds
Number of subjects: 0
Study: 6143579

Group type: EXPERIMENTAL
Intervention: Pipotiazine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 31262924

Group type: EXPERIMENTAL
Intervention: Oblate-covered everolimus
Number of subjects: 79

Group type: COMPARATOR
Intervention: Non-oblate everolimus
Number of subjects: 79

Group type: COMPARATOR
Intervention: Non-oblate everolimus followed by oblate-covered everolimus
Number of subjects: 79
Study: 29253847

Group type: EXPERIMENTAL
Intervention: Nalbuphine ER 120 mg
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study: 26880679

Group type: EXPERIMENTAL
Intervention: Photographic display
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Photographic display combined with music
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (standard intervention)
Number of subjects: 180
Study: 25514079

Group type: EXPERIMENTAL
Intervention: NuSmile® crowns
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Kinder Krowns® crowns
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Parental satisfaction
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Primary maxillary first molar crowns
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Primary mandibular second molar crowns
Number of subjects: 36
Study: 22110019

Group type: EXPERIMENTAL
Intervention: Baseline galectin-3 levels
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Baseline galectin-3 above the median
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Galectin-3 quartile relationship with HF risk
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: BNP added to the model
Number of subjects: 100
Study: 19224305

Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Obturator nerve block
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (sham block)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups (Femoral, Obturator, Placebo)
Number of subjects: 30
Study: 17465658

Group type: EXPERIMENTAL
Intervention: Bleaching with 35% hydrogen peroxide
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bleaching with 35% hydrogen peroxide + UltraEZ desensitizer
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: UltraEZ desensitizer alone
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no bleaching or desensitizer)
Number of subjects: 48
Study: 15121021

Group type: EXPERIMENTAL
Intervention: 1 mg iv ibandronate injections
Number of subjects: 2862

Group type: EXPERIMENTAL
Intervention: 0.5 mg iv ibandronate injections
Number of subjects: 2862

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2862
Study: 11298697

Group type: EXPERIMENTAL
Intervention: Educational programme
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (no educational programme)
Number of subjects: 107
Study: 9461704

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with monitoring of myoglobin concentration, CPK, and CK-MB activity.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Monitoring of myoglobin concentration, CPK, and CK-MB activity at 3 hours post-thrombolytic treatment.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Reduction of total elevations of the ST segment 70% or more in electrocardiographic recording performed 3 hours after thrombolytic treatment.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Reduction of total elevations of the ST segment less than 30%.
Number of subjects: 50
Study: 7948319

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study: 3300425

Group type: EXPERIMENTAL
Intervention: 1.1% lidocaine carbonate
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1% lidocaine hydrochloride
Number of subjects: 50
Study: 28620791

Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 358

Group type: COMPARATOR
Intervention: Tolterodine
Number of subjects: 358
Study: 27370230

Group type: COMPARATOR
Intervention: Metformin with placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin with placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin with atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 0
Study: 25687344

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 387

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 387
Study: 23608625

Group type: EXPERIMENTAL
Intervention: Biotene OralBalance® gel
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 41
Study: 19931408

Group type: EXPERIMENTAL
Intervention: human insulin B‐chain in incomplete Freund's adjuvant (IFA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 18539460

Group type: COMPARATOR
Intervention: Eyes closed with no instructions (EC‐NI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eyes open with instructions to gaze at a stationary black dot (EO‐WI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eyes closed with instructions to imagine looking at the same target (EC‐WI)
Number of subjects: 10
Study: 16500657

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 873

Group type: COMPARATOR
Intervention: Combination of Sulphadoxine-pyrimethamine and Artesunate (SP+AS)
Number of subjects: 873
Study: 14645311

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 to 20 mg/d) with prophylactic benztropine (1 to 4 mg/d)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Haloperidol (5 to 20 mg/d)
Number of subjects: 309
Study: 10946101

Group type: EXPERIMENTAL
Intervention: Isokinetic peak torque in healthy subjects
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Average power in healthy subjects
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Total work in healthy subjects
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isometric peak torque extension in healthy subjects
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isokinetic peak torque in patients
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Average power in patients
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Total work in patients
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isometric peak torque extension in patients
Number of subjects: 36
Study: 9057170

Group type: COMPARATOR
Intervention: Control (blood transfusion history)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Cases (blood transfusion history)
Number of subjects: 656
Study: 8103365

Group type: EXPERIMENTAL
Intervention: Abdominal rectopexy with absorbable mesh made of polyglycolic acid (n = 17)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Abdominal rectopexy with absorbable mesh made of polyglactine 910 (n = 30)
Number of subjects: 47
Study: 3089683

Group type: EXPERIMENTAL
Intervention: Ovral (50 micrograms ethinyloestradiol, EE2 and 500 micrograms levonorgestrel, LNG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nordette (30 micrograms EE2 and 150 micrograms LNG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norminest (35 micrograms EE2 and 500 micrograms norethisterone, NOR)
Number of subjects: 0
Study: 30296537

Group type: EXPERIMENTAL
Intervention: Local excision margin (EM) >2 cm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local destruction method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EM >2 cm in patients <60 years of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EM >2 cm in patients with smaller tumor diameters (T1 and T2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EM >2 cm in patients who underwent adjuvant radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Different EMs in patients ≥75 years of age or stage III tumors
Number of subjects: 0
Study: 31109198

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 400 or 800 mg, once daily for 3 consecutive days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27455856

Group type: EXPERIMENTAL
Intervention: Non-Latino Black MSM
Number of subjects: 39301

Group type: EXPERIMENTAL
Intervention: Foreign birth (compared to US birth) for Black MSM
Number of subjects: 39301

Group type: EXPERIMENTAL
Intervention: Foreign birth (compared to US birth) for White MSM
Number of subjects: 39301

Group type: EXPERIMENTAL
Intervention: Rural residence for Black MSM
Number of subjects: 39301

Group type: EXPERIMENTAL
Intervention: Rural residence for Latino MSM
Number of subjects: 39301

Group type: EXPERIMENTAL
Intervention: Rural residence for White MSM
Number of subjects: 39301
Study: 25907999

Group type: EXPERIMENTAL
Intervention: 0.0015% Tafluprost ophthalmic solution
Number of subjects: 246

Group type: COMPARATOR
Intervention: 0.005% Latanoprost ophthalmic solution
Number of subjects: 246
Study: 23474911

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 91
Study: 21831448

Group type: EXPERIMENTAL
Intervention: Adjunctive creatine 4 g daily for 8 weeks
Number of subjects: 5

Group type: COMPARATOR
Intervention: Healthy controls (10 female adolescents)
Number of subjects: 5
Study: 19487931

Group type: EXPERIMENTAL
Intervention: FDG PET/computed tomography of the thorax
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 10
Study: 17260705

Group type: EXPERIMENTAL
Intervention: Nutritional and non-nutritional interventions
Number of subjects: 0
Study: 15537557

Group type: EXPERIMENTAL
Intervention: Bupropion 150 mg/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 11262678

Group type: EXPERIMENTAL
Intervention: Post administration of the VCM1 questionnaire
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Telephone administration of the VCM1 questionnaire
Number of subjects: 188
Study: 9557911

Group type: EXPERIMENTAL
Intervention: Esmolol 4.0 mg.kg(‐1) IV given 90 secs prior to tracheal intubation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esmolol 2.0 mg.kg(‐1) IV given 60 secs prior to eye bandaging and tracheal extubation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline 1.0 ml. 10kg(‐1) prior to tracheal intubation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline 0.5 ml. 10kg(‐1) prior to eye bandaging and tracheal extubation
Number of subjects: 0
Study: 7741667

Group type: EXPERIMENTAL
Intervention: Classical Chinese needle acupuncture for 5 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo procedure (mock electrical stimulation)
Number of subjects: 20
Study: 2758870

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g (i.m.) every 24 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefotaxime 1 g (i.m.) every 12 h
Number of subjects: 0
Study: 7769502

Group type: EXPERIMENTAL
Intervention: Quinapril hydrochloride, once a day for 8 weeks, with optional titration to a higher dose after 4 weeks based on DBP response.
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo, once a day for 8 weeks.
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Quinapril hydrochloride (low dose), once a day for 8 weeks.
Number of subjects: 135
Study: 581116

Group type: EXPERIMENTAL
Intervention: Micronized oestradiol (1, 2 or 4 mg)
Number of subjects: 10
Study: 31820515

Group type: EXPERIMENTAL
Intervention: Mentholated popsicle
Number of subjects: 40

Group type: COMPARATOR
Intervention: Absolute fasting
Number of subjects: 40
Study: 31044733

Group type: EXPERIMENTAL
Intervention: Heavy liquid used during the procedure
Number of subjects: 49

Group type: COMPARATOR
Intervention: No heavy liquid used during the procedure
Number of subjects: 49
Study: 28328303

Group type: EXPERIMENTAL
Intervention: 11 sessions of cell phone-delivered smoking cessation treatment
Number of subjects: 474

Group type: COMPARATOR
Intervention: Usual care (cessation advice and self-help materials)
Number of subjects: 474
Study: 24852505

Group type: EXPERIMENTAL
Intervention: Individualized treatment (specific, individualized postural and movement retraining, stretching, and functional weight‐bearing, strengthening exercises)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Local quadriceps strengthening, quadriceps stretching, and taping
Number of subjects: 41
Study: 23431266

Group type: EXPERIMENTAL
Intervention: HSL inhibitor treatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: HSL gene silencing in human adipocytes
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Chronic inhibition of lipolysis
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Blunted lipolytic capacity in HSL haploinsufficient mice
Number of subjects: 2
Study: 21301698

Group type: EXPERIMENTAL
Intervention: GPs' usual assessment
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Lifescripts tool
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Steps per day (cut-off of 7500 steps/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (usual assessment)
Number of subjects: 29
Study: 19566639

Group type: EXPERIMENTAL
Intervention: Self-management education program (12 months duration, <30 min monthly interviews, biweekly telephone calls)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Self-management education program
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual clinical practice (control group)
Number of subjects: 75
Study: 17415766

Group type: EXPERIMENTAL
Intervention: Targobone (bovine collagen and teicoplanin)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Autologous bone grafts
Number of subjects: 21
Study: 15292108

Group type: EXPERIMENTAL
Intervention: Oral L-carnitine (2 g/d) + acetyl-L-carnitine (1 g/d)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: L-carnitine/acetyl-L-carnitine + 1 x 30-mg cinnoxicam suppository every 4 days
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 12008655

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody therapy with autologous peripheral blood stem cell transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monoclonal antibodies
Number of subjects: 0
Study: 9718250

Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kappa-opioid receptor agonist (7.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7858067

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study: 2684451

Group type: EXPERIMENTAL
Intervention: Iontophoresis of lignocaine
Number of subjects: 46
Study: 1107508

Group type: EXPERIMENTAL
Intervention: Brush only (modified Bass brushing technique)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Brush and floss
Number of subjects: 24

Group type: COMPARATOR
Intervention: Brush and rubber tip
Number of subjects: 24

Group type: COMPARATOR
Intervention: Brush, floss and rubber tip
Number of subjects: 24
Study: 31343586

Group type: EXPERIMENTAL
Intervention: G1: inspiratory muscle training, active upper limb and lower limb exercise training, and early ambulation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: G2: same protocol as G1 without inspiratory muscle training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: G3: inspiratory muscle training alone
Number of subjects: 40

Group type: COMPARATOR
Intervention: G4: control
Number of subjects: 40
Study: 29150470

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: PRP injection
Number of subjects: 230
Study: 25421879

Group type: EXPERIMENTAL
Intervention: Nebulized sodium nitrite (AIR001) at a maximum tolerated dose (MTD) of 90 mg administered every 8 hours for 6 days
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Nebulized sodium nitrite (AIR001) at higher dosage levels (120 mg and 176 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Nebulized sodium nitrite (AIR001) under conditions of mild hypoxia and co-administration with sildenafil
Number of subjects: 82
Study: 22990219

Group type: EXPERIMENTAL
Intervention: CO criterion for abstinence below 5 ppm (≤4 ppm)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: CO criterion for abstinence below 9 ppm
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: High quit interest
Number of subjects: 261

Group type: COMPARATOR
Intervention: Reinforcement of abstinence
Number of subjects: 261
Study: 21496509

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) for PTSD
Number of subjects: 150